Table 2

Profile of PBMCs of NXS2 tumor-bearing mice after 3 days of antitumor therapy

Treatment groupa% positively staining PBMCsb
CD4CD8B220DX5
PBS49c15254
Hu14.18-IL23783326
IL-2 infusion39103117
Hu14.18-IL2 + IL2 infusion1772045
  • a Mice bearing s.c. NXS2 tumors were treated with hu14.18-IL2 (5 μg/day × 5 days beginning on day 9 posttumor injection), recombinant human IL-2 (50,000 IU/day × 7 days beginning on day 7 posttumor injection), or the combined hu14.18-IL2 and recombinant human IL-2 therapy and evaluated 20 h after the third-day injection of hu14.18-IL2. Blood samples from four individual mice/group were obtained and pooled for each treatment group. Flow cytometric analysis was performed as described in “Materials and Methods.”

  • b PBMC, peripheral blood mononuclear cell; IL-2, interleukin 2.

  • c Numbers reflect the percentage of viable cells staining positive for cell surface markers CD4, CD8, B220, or DX5 from the population of gated lymphocytes.